Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CLK inhibitor BH-30236

An orally bioavailable macrocyclic ATP-competitive inhibitor of CDC2-like kinase (CLK) family kinases, including CLK1, CLK2 and CLK4, with potential antineoplastic activity. Upon oral administration, CLK inhibitor BH-30236 targets, binds to and inhibits the activity of CLK1/2/4, thereby inhibiting the phosphorylation of serine/arginine-rich (SR) domain-containing splicing factors (SFs). This modulates RNA splicing, prevents the expression of certain tumor-associated genes, and inhibits tumor cell proliferation. In many cancer cells, core spliceosome proteins, including SF3B1, U2 small nuclear ribonucleoprotein auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2) and U2 small nuclear ribonucleoprotein auxiliary factor subunit-related protein 2 (ZRSR2), are mutated and aberrantly activated leading to a dysregulation of mRNA splicing. CLK family kinases, an evolutionarily conserved group of kinases, phosphorylates various SR proteins including SR domain-containing SFs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CLK1/2/4 inhibitor BH-30236
Code name:BH 30236
BH-30236
BH30236
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search